Passive immune protection by herpes simplex virus-specific monoclonal antibodies with different plaque development inhibition activity.
A series of herpes simplex viruses type 1 (HSV-1) neutralizing monoclonal antibodies (mAbs) with different plaque development inhibition (PDI) activity were tested for passive protection in mice. When virus was inoculated intracranially, mAbs with PDI activity were not more protective than mAbs without PDI activity. However, when virus was inoculated percutaneously, there was a trend indicating that neutralizing mAbs with PDI power were more active in protecting mice from the cutaneous lesion than mAbs without PDI power. The results are discussed in relation to the possible involvement of PDI activity in in vivo protection and to the fact that this mechanism of protection might operate in cutaneous, but not in nervous tissue.